Molecular analysis of the <i>Rh</i> locus in a person with the D<sup>u</sup> phenotype

Spence, W. Christine; Maddalena, Anne; Demers, Daniel B.; Bick, David

doi:10.1046/j.1537-2995.1994.34894353477.x

Cited by 6 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, evidence of partial deletions of the RHD gene has shown that DNA-based genotyping techniques are not without error. To date, the errors in DNA-based genotyping have been associated with the Cde haplotype (Hyland et al, 1994b;Simsek et al, 1994), dCce s (Blunt et al, 1994), RhD u (Spence et al, 1994), RhD DBT (Beckers et al, 1996) and RhD VI variants (Hyland et al, 1994b;Mouro et al, 1994;Rouillac et al, 1995).…”

Section: Discussionmentioning

confidence: 99%

RhD status of a fetus at risk for haemolytic disease with a discrepant maternal DNA-based RhD genotype

et al. 1999

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

RhD status of a fetus at risk for haemolytic disease with a discrepant maternal DNA-based RhD genotype

et al. 1999

View full text Add to dashboard Cite

“…The first paper in this area appeared in TRANSFUSION in 1990, 1 a review on the cloning of ABH; several other reviews followed in 1991 2 and 1992 3,4 . The first research reports in this area were published in TRANSFUSION in 1994, one on platelets (PLTs) 5 and one on red blood cells (RBCs) 6 . From 2000 to 2005, about one‐third of the papers submitted to the immunohematology section, and accepted for publication, were DNA based; in 2006 they represented 50% of the accepted papers in this section, and in 2007 they reached a peak, just exceeding serologic investigations (including a special supplement of TRANSFUSION devoted to DNA‐based approaches).…”

mentioning

confidence: 99%

A new section, “blood group genomics,” with a new associate editor

Garratty¹,

Ness²

2010

Transfusion

View full text Add to dashboard Cite

A new section, "blood group genomics," with a new associate editor_ 2923 2528T he application of DNA analysis to blood group antigens started in the early 1990s. The first paper in this area appeared in TRANSFUSION in 1990, 1 a review on the cloning of ABH; several other reviews followed in 1991 2 and 1992. 3,4 The first research reports in this area were published in TRANSFU-SION in 1994, one on platelets (PLTs) 5 and one on red blood cells (RBCs). 6 From 2000 to 2005, about one-third of the papers submitted to the immunohematology section, and accepted for publication, were DNA based; in 2006 they represented 50% of the accepted papers in this section, and in 2007 they reached a peak, just exceeding serologic investigations (including a special supplement of TRANSFUSION devoted to DNA-based approaches). This supplement presented the content of a "Workshop on Molecular Methods in Immunohematology," sponsored by the FDA/CBER, OS/Office of Public Health, and the NHLBI. The workshop took place at the end of 2006. In a summary of the meeting by Garratty, entitled "Where are we, and where are we going, with DNA-based approaches in immunohematology? Is serology finished?" he concluded that serology is not finished, will be needed for many years, and will be a necessary partner for the rapidly increasing applications of DNA-based approaches. 7 Other authors have agreed. 8,9 At present (20088,9 At present ( -2010, the number of publications in the two main areas of immunohematology is almost equal. Almost 700 papers were submitted to TRANSFU-SION in 2009 and about the same in 2010. Approximately 10% of these were sent to the immunohematology section associate editor to process (select reviewers; suggest "accept," "revise," or "reject"; process revisions, make final decision). The immunohematology section deals with blood group antigens and antibodies (RBCs, WBCs, PLTs). It covers genetics, some structural aspects of the RBC membrane, serology, investigations at the DNA level, and some miscellaneous aspects of RBC, PLT, and WBC immunology. Approximately 60% of these papers were accepted for publication.Thus, it seems an appropriate time for TRANSFU-SION to make a separate section called "blood group genomics." This section will cover the molecular biology of RBCs, WBCs, and PLTs. We are fortunate to be able to announce that Dr Connie Westhoff (now at the New York Blood Center) has accepted our invitation to become a new associate editor who will handle this section. In addition to her DNA expertise, Connie is an expert serologist and will be an ideal person to also back up Dr Garratty in other aspects of immunohematology. We suspect that in the New Year you will be seeing some new requirements/ advice when submitting DNA-based papers to TRANSFU-SION! We both welcome Connie to her new position as associate editor of a new section in TRANSFUSION.

show abstract

Molecular analysis of the rhd genotype in fetuses at risk for rhd hemolytic disease

Maddalena

et al. 1995

Obstetrics & Gynecology

View full text Add to dashboard Cite

The objective of this study was to evaluate the accuracy of a DNA-based testing methodology in determining the RhD genotypes of fetuses at risk for RhD hemolytic disease. We designed a multiplex polymerase chain reaction-based test based on recent RhD and RhCE sequence information. To improve the accuracy of the results, two different portions of the RhD gene were examined. Deoxyribonucleic acid was extracted from fetal specimens, portions of the RhD gene were amplified by the polymerase chain reaction, and the amplified product was run on a polyacrylamide gel to look for the presence or absence of the RhD gene. We tested 67 amniotic fluid and two chorionic villus specimens to determine the fetal RhD genotype in pregnancies at risk for RhD hemolytic disease. Forty-seven of the 69 specimens were determined to be Rh-positive, and 22 were Rh-negative. Fifty of the 69 fetal specimens--31 Rh-positive and 19 Rh-negative--were serotyped at birth. In all 50, there was complete correlation between the DNA analysis and the serotyping results. RhD gene analysis is a rapid and reliable method that provides an accurate fetal genotype to aid in the prenatal care of RhD-alloimmunized women.

show abstract

Molecular analysis of the Rh locus in a person with the D^u phenotype

Cited by 6 publications

References 4 publications

RhD status of a fetus at risk for haemolytic disease with a discrepant maternal DNA-based RhD genotype

RhD status of a fetus at risk for haemolytic disease with a discrepant maternal DNA-based RhD genotype

A new section, “blood group genomics,” with a new associate editor

Molecular analysis of the rhd genotype in fetuses at risk for rhd hemolytic disease

Contact Info

Product

Resources

About

Molecular analysis of the Rh locus in a person with the Du phenotype

Cited by 6 publications

References 4 publications

RhD status of a fetus at risk for haemolytic disease with a discrepant maternal DNA-based RhD genotype

RhD status of a fetus at risk for haemolytic disease with a discrepant maternal DNA-based RhD genotype

A new section, “blood group genomics,” with a new associate editor

Molecular analysis of the rhd genotype in fetuses at risk for rhd hemolytic disease

Contact Info

Product

Resources

About

Molecular analysis of the Rh locus in a person with the D^u phenotype